Feasibility study on pre or postoperative accelerated radiotherapy (POP-ART) in breast cancer patients
Authors:
- Hans Van HulleHHHans Van Hulle
- Vincent VakaetVVVincent Vakaet
- Giselle PostGPGiselle Post
- Annick Van GrevelingAGAnnick Van Greveling
- Chris MontenCMChris Monten
- An HendrixAHAn Hendrix
- Koen Van de VijverKVKoen Van de Vijver
- Jo Van DorpeJDJo Van Dorpe
- Pieter De VisscherePVPieter De Visschere
- Geert BraemsGBGeert Braems
- Katrien VandecasteeleKVKatrien Vandecasteele
- Hannelore DenysHDHannelore Denys
Open Access
- 10 October 2020
- journal article
- research article
- Published by Springer Nature in Pilot and Feasibility Studies
- Vol. 6 (1) , 1-8
Abstract
Background: In early-stage breast cancer, the cornerstone of treatment is surgery. After breast-conserving surgery, adjuvant radiotherapy has shown to improve locoregional control and overall survival rates. The use of breast radiotherapy in the preoperative (preop) setting is far less common. Nevertheless, it might improve disease-free survival as compared to postoperative radiotherapy. There is also a possibility of downsizing the tumour which might lead to a lower need for mastectomy. There are some obstacles that complicate its introduction into daily practice. It may complicate surgery or lead to an increase in wound complications or delayed wound healing. Another fear of preop radiotherapy is delaying surgery for too long. At Ghent University Hospital, we have experience with a 5-fraction radiotherapy schedule allowing radiotherapy delivery in a very short time span. Methods: Twenty female breast cancer patients with non-metastatic disease receiving preop chemotherapy will be randomized between preop or postoperative radiotherapy. The feasibility of preop radiotherapy will be evaluated based on overall treatment time. All patients will be treated in 5 fractions of 5.7 Gy to the whole breast with a simultaneous integrated boost to the tumour/tumour bed of 5 × 6.2 Gy. In case of lymph node irradiation, the lymph node regions will receive a dose of 27 Gy in 5 fractions of 5.4 Gy. The total duration of therapy will be 10 to 12 days. In the preop group, overall treatment time is defined as the time between diagnosis and the day of last surgery, in the postop group between diagnosis and last irradiation fraction. Toxicity related to surgery, radio-, and chemotherapy will be evaluated on dedicated case-report forms at predefined time points. Tumour response will be evaluated on the pathology report and on MRI at baseline and in the interval between chemotherapy and surgery. Discussion: The primary objective of the trial is to investigate the feasibility of preop radiotherapy. Secondary objectives are to search for biomarkers of response and toxicity and identify the involved cell death mechanisms and the effect of preop breast radiotherapy on the in-situ immune micro-environment.Keywords
Funding Information
- Kom op tegen Kanker
This publication has 62 references indexed in Scilit:
- Radiation as an immunological adjuvant: current evidence on dose and fractionationFrontiers in Oncology, 2012
- Dying cell clearance and its impact on the outcome of tumor radiotherapyFrontiers in Oncology, 2012
- Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trialsThe Lancet, 2011
- In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survivalThe Journal of Pathology, 2011
- Development and Validation of a Heart Atlas to Study Cardiac Exposure to Radiation Following Treatment for Breast CancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Long-Term Results of Hypofractionated Radiation Therapy for Breast CancerNew England Journal of Medicine, 2010
- Combining radiation, immunotherapy, and antiangiogenesis agents in the management of cancer: the Three Musketeers or just another quixotic combination?Molecular BioSystems, 2009
- Development of a New Patient-Reported Outcome Measure for Breast Surgery: The BREAST-QPlastic and Reconstructive Surgery, 2009
- Systemic effects of local radiotherapyThe Lancet Oncology, 2009
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008